{"entity":"gilead-sciences","id":"ent_gilead-sciences","name":"Gilead Sciences","wikidata":"Q663596","page":"https://asof.is/record/gilead-sciences","summary":"Gilead Sciences is an American biopharmaceutical company, headquartered in Foster City. It reported revenue of $28.75B for the period ended December 31, 2024.","title":"Gilead Sciences: revenue $28.75B","key_facts":[{"label":"CFO","value":"Andrew D. Dickinson","claim":"clm_012FF580C6B9"},{"label":"Headquarters","value":"Foster City","claim":"clm_3AA77CFFBA18"},{"label":"Revenue","value":"$28.75B","recorded":"28,754,000,000 United States dollar","note":"to 2024-12-31","claim":"clm_766F0DC2656D"},{"label":"Ticker","value":"GILD · Nasdaq","claim":"clm_ACCCAF058EE1"}],"faq":[{"question":"Where is Gilead Sciences headquartered?","answer":"Foster City."},{"question":"What is Gilead Sciences's revenue?","answer":"$28.75B for the period ended December 31, 2024."}],"as_of":"2025-11-08","known_by":null,"since":null,"fact_pages":[{"predicate":"cfo","page":"https://asof.is/record/gilead-sciences/cfo","md":"https://asof.is/record/gilead-sciences/cfo.md","json":"https://asof.is/v1/entities/gilead-sciences/cfo"},{"predicate":"headquarters","page":"https://asof.is/record/gilead-sciences/headquarters","md":"https://asof.is/record/gilead-sciences/headquarters.md","json":"https://asof.is/v1/entities/gilead-sciences/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/gilead-sciences/revenue","md":"https://asof.is/record/gilead-sciences/revenue.md","json":"https://asof.is/v1/entities/gilead-sciences/revenue"},{"predicate":"net_income","page":"https://asof.is/record/gilead-sciences/net_income","md":"https://asof.is/record/gilead-sciences/net_income.md","json":"https://asof.is/v1/entities/gilead-sciences/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/gilead-sciences/operating_income","md":"https://asof.is/record/gilead-sciences/operating_income.md","json":"https://asof.is/v1/entities/gilead-sciences/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/gilead-sciences/quarterly_revenue","md":"https://asof.is/record/gilead-sciences/quarterly_revenue.md","json":"https://asof.is/v1/entities/gilead-sciences/quarterly_revenue"}],"products":[],"coverage":{"entity":"gilead-sciences","name":"Gilead Sciences","kind":"organization","sources":[{"source":"wikidata","item":"Q663596","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":882095,"ticker":"GILD","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":537,"open":25,"retracted":0,"first":"1987-06-01","predicates":{"shares_outstanding":{"claims":70,"open":1,"kind":"fact"},"cfo":{"claims":1,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":56,"open":1,"kind":"fact"},"total_equity":{"claims":73,"open":1,"kind":"fact"},"total_assets":{"claims":71,"open":1,"kind":"fact"},"operating_income":{"claims":19,"open":1,"kind":"fact"},"quarterly_operating_income":{"claims":56,"open":1,"kind":"fact"},"net_income":{"claims":19,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":51,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":56,"open":1,"kind":"fact"},"quarterly_research_and_development":{"claims":25,"open":1,"kind":"fact"},"revenue":{"claims":19,"open":1,"kind":"fact"},"cik":{"claims":1,"open":1,"kind":"identifier"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"agreement":{"claims":2,"open":2,"kind":"event"},"website":{"claims":1,"open":1,"kind":"identifier"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"research_and_development":{"claims":9,"open":1,"kind":"fact"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"x_username":{"claims":1,"open":1,"kind":"identifier"},"registrant_name":{"claims":1,"open":1,"kind":"fact"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":535,"last_added":"2026-11-08","last_checked":"2026-11-09","last_verified":null},{"origin":"wikidata","label":"Wikidata statements that cite a reference URL (wikidata_ingest.py)","claims":2,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_BEFBDF4F70C1","predicate":"agreement","value":"CymaBay Therapeutics, Inc.","valid_from":"2024-02-11","valid_to":null,"published":"2024-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences agreement: CymaBay Therapeutics, Inc.\", as of 2024-02-11. Claim clm_BEFBDF4F70C1, https://asof.is/claim/clm_BEFBDF4F70C1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000095010324002027/0000950103-24-002027-index.htm.","url":"https://asof.is/claim/clm_BEFBDF4F70C1","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000095010324002027/0000950103-24-002027-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K","published_at":"2024-02-12T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"On February 11, 2024, Gilead Sciences, Inc., a Delaware corporation (“ Parent ” or “ Gilead ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), among Parent, CymaBay Therapeutics, Inc., a Delaware corporation (the “ Company ”),","url":"https://www.sec.gov/Archives/edgar/data/882095/000095010324002027/0000950103-24-002027-index.htm"}},{"id":"clm_7B68B20F3E17","predicate":"cash_and_equivalents","value":"5,412,000,000 United States dollar","valid_from":"2022-12-31","valid_to":null,"published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 5,412,000,000 United States dollar\", as of 2022-12-31. Claim clm_7B68B20F3E17, https://asof.is/claim/clm_7B68B20F3E17, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm.","url":"https://asof.is/claim/clm_7B68B20F3E17","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2022, filed 2023-02-22"}},{"id":"clm_012FF580C6B9","predicate":"cfo","value":"Andrew D. Dickinson","valid_from":null,"undated":true,"valid_to":null,"published":"2026-03-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cfo: Andrew D. Dickinson\", undated. Claim clm_012FF580C6B9, https://asof.is/claim/clm_012FF580C6B9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000130817926000106/gild014721-def14a.htm.","url":"https://asof.is/claim/clm_012FF580C6B9","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000130817926000106/gild014721-def14a.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-03-20T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"Andrew D. Dickinson Age: 56 Joined Gilead: 2016 Position: ► Chief Financial Officer","url":"https://www.sec.gov/Archives/edgar/data/882095/000130817926000106/gild014721-def14a.htm"}},{"id":"clm_3A93D2D56CBA","predicate":"cik","value":"0000882095","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cik: 0000882095\", undated. Claim clm_3A93D2D56CBA, https://asof.is/claim/clm_3A93D2D56CBA, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_3A93D2D56CBA","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_58190642DD33","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences fiscal year end: 12-31\", undated. Claim clm_58190642DD33, https://asof.is/claim/clm_58190642DD33, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_58190642DD33","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_3AA77CFFBA18","predicate":"headquarters","value":"Foster City","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences headquarters: Foster City\", undated. Claim clm_3AA77CFFBA18, https://asof.is/claim/clm_3AA77CFFBA18, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_3AA77CFFBA18","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_79DB7756109C","predicate":"listed_on","value":"Nasdaq","valid_from":null,"undated":true,"valid_to":null,"published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences listed on: Nasdaq\", undated. Claim clm_79DB7756109C, https://asof.is/claim/clm_79DB7756109C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_79DB7756109C","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":"2018-02-27T00:00:00+00:00"},{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_D66A9204BCB4","predicate":"net_income","value":"480,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 480,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_D66A9204BCB4, https://asof.is/claim/clm_D66A9204BCB4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_D66A9204BCB4","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_075AC6F097D8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-28"}},{"id":"clm_9D8D94D516C5","predicate":"operating_income","value":"1,662,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 1,662,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_9D8D94D516C5, https://asof.is/claim/clm_9D8D94D516C5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_9D8D94D516C5","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_44AE227A69DA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-28"}},{"id":"clm_8C716505DCB2","predicate":"quarterly_net_income","value":"3,052,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 3,052,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_8C716505DCB2, https://asof.is/claim/clm_8C716505DCB2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_8C716505DCB2","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_24FF1FC3A935","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_E88E046C7258","predicate":"quarterly_operating_income","value":"3,327,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 3,327,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_E88E046C7258, https://asof.is/claim/clm_E88E046C7258, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_E88E046C7258","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3305AD308056","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_46B555B900FF","predicate":"quarterly_research_and_development","value":"1,101,000,000 United States dollar","valid_from":"2020-03-31","valid_to":null,"published":"2020-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 1,101,000,000 United States dollar\", as of 2020-03-31. Claim clm_46B555B900FF, https://asof.is/claim/clm_46B555B900FF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm.","url":"https://asof.is/claim/clm_46B555B900FF","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2020, filed 2020-05-06"}},{"id":"clm_3A5203A42518","predicate":"quarterly_revenue","value":"7,769,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,769,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_3A5203A42518, https://asof.is/claim/clm_3A5203A42518, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_3A5203A42518","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5B00A751741D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_B758636654A0","predicate":"registrant_name","value":"GILEAD SCIENCES, INC.","valid_from":"1994-02-14","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences registrant name: GILEAD SCIENCES, INC.\", as of 1994-02-14. Claim clm_B758636654A0, https://asof.is/claim/clm_B758636654A0, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_B758636654A0","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_EF2F795524C5","predicate":"research_and_development","value":"9,106,000,000 United States dollar","valid_from":"2019-12-31","valid_to":null,"published":"2020-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences research and development: 9,106,000,000 United States dollar\", as of 2019-12-31. Claim clm_EF2F795524C5, https://asof.is/claim/clm_EF2F795524C5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm.","url":"https://asof.is/claim/clm_EF2F795524C5","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2019, filed 2020-02-25"}},{"id":"clm_766F0DC2656D","predicate":"revenue","value":"28,754,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 28,754,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_766F0DC2656D, https://asof.is/claim/clm_766F0DC2656D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_766F0DC2656D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5E2D1C5DC1DC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-28"}},{"id":"clm_5E452E3F3A54","predicate":"shares_outstanding","value":"1,240,679,623 shares","valid_from":"2025-10-31","valid_to":"2026-02-13","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,240,679,623 shares\", as of 2025-10-31 (until 2026-02-13). Claim clm_5E452E3F3A54, https://asof.is/claim/clm_5E452E3F3A54, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_5E452E3F3A54","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E2DB5E0B53B4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_44B0DF6C61E1","predicate":"sic_industry","value":"Biological Products, (No Diagnostic Substances) (2836)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences sic industry: Biological Products, (No Diagnostic Substances) (2836)\", undated. Claim clm_44B0DF6C61E1, https://asof.is/claim/clm_44B0DF6C61E1, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_44B0DF6C61E1","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_433BC2407C2F","predicate":"state_of_incorporation","value":"DE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences state of incorporation: DE\", undated. Claim clm_433BC2407C2F, https://asof.is/claim/clm_433BC2407C2F, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_433BC2407C2F","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_ACCCAF058EE1","predicate":"ticker","value":"GILD","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences ticker: GILD\", undated. Claim clm_ACCCAF058EE1, https://asof.is/claim/clm_ACCCAF058EE1, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_ACCCAF058EE1","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_5B9243C901AF","predicate":"total_assets","value":"58,533,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 58,533,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_5B9243C901AF, https://asof.is/claim/clm_5B9243C901AF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_5B9243C901AF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_06C160F8C3A5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_B2A4004D2607","predicate":"total_equity","value":"21,540,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 21,540,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_B2A4004D2607, https://asof.is/claim/clm_B2A4004D2607, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_B2A4004D2607","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_994B784F55A6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_6FC170F46335","predicate":"website","value":"https://www.gilead.com/","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences website: https://www.gilead.com/\", undated. Claim clm_6FC170F46335, https://asof.is/claim/clm_6FC170F46335, accessed 2026-11-10. Source: https://www.wikidata.org/wiki/Q663596.","url":"https://asof.is/claim/clm_6FC170F46335","accessed":"2026-11-10"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"Gilead Sciences.","url":"https://www.gilead.com/"}},{"id":"clm_B694320241BE","predicate":"x_username","value":"GileadSciences","valid_from":"2011-06-02","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences x username: GileadSciences\", as of 2011-06-02. Claim clm_B694320241BE, https://asof.is/claim/clm_B694320241BE, accessed 2026-11-10. Source: https://www.wikidata.org/wiki/Q663596.","url":"https://asof.is/claim/clm_B694320241BE","accessed":"2026-11-10"},"confidence":0.6,"status":"unverified","assertable":false,"why_not":"unverified","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"https://twitter.com/GileadSciences","url":"https://www.gilead.com/"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{"low_confidence":"Confidence below 0.5, the line the record asserts at.","unverified":"Unverified: one source that is not primary, or a primary source below confidence 0.7. Asserted once a primary source or a second independent domain confirms it."},"checked_by":{"page-read":"its source page states the value and the date","sec-filing":"parsed from the SEC filing","own-site":"the entity's own site names it (a website whose page names the entity, a handle its website links to)"}}}